Avtor/Urednik		Keber, I; Lavre, J; Šuc, S; Keber, D
Naslov		The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates
Tip		članek
Vir		Fibrinolysis
Vol. in št.		Letnik 8, št. Suppl 2
Leto izdaje		1994
Obseg		str. 57-9
Jezik		eng
Abstrakt		Impaired fibrinolysis due to a high level of plasminogen activator inhibitor-1 (PAI-1) has been reported in patients with hypertriglyceridemia. We studied the fibriolytic effects of the hypolipemic drugs gemfibrozil and fenofibrate that mainly affect triglyceride-rich lipoproteins in 27 patients with severe hypertriglyceridemia (Fredrickson's type IV and V). After a wash-out period of 4 weeks the patients were randomly cross-treated with gemfibrozil (600 mg b.i.d.) and fenofibrate (250 mg daily), each time for 6 weeks. Tissue-type plasminogen activator (t-PA) antigen, t-PA activity, PAI-1 antigen, PAI activity and serum lipides were measured before and after the 6 weeks of either treatment. Basal levels of PAI-1 antigen and activity were very high and did not change after any treatment in the whole group of patients, while the mean triglyceride level decreased by 49 percent after gemfibrozil and by 39 percent after fenofibrate. However, a significant decrease in PAI-1 antigen was observed in a subgroup of 9 patients treated with gemfibrozil, in whom triglycerides decreased to or below 2.8 mmol/L. In all patients t-PA antigen decreased significantly after treatment with either drug, while t-PA activity decreased only after fenofibrate. It was concluded that almost normal values of triglycerides should be achieved during treatment with fibrates in order to decrease high PAI-1 antigen and activity levels. On the other hand, the decrease of t-PA antigen during fibrate treatment seems not to be associated with the degree of triglyceride-lowering effects of these drugs.
Deskriptorji		HYPERTRIGLYCERIDEMIA PLASMINOGEN ACTIVATOR INHIBITOR 1 TRIGLYCERIDES PROCETOFEN GEMFIBROZIL